onr:"swepub:oai:DiVA.org:umu-120005"
Sökning: onr:"swepub:oai:DiVA.org:umu-120005" > A novel oral insuli...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04349naa a2200529 4500 | |
| 001 | oai:DiVA.org:umu-120005 | |
| 003 | SwePub | |
| 008 | 160504s2016 | |||||||||||000 ||eng| | |
| 009 | oai:DiVA.org:uu-268087 | |
| 009 | oai:prod.swepub.kib.ki.se:132884147 | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1200052 URI |
| 024 | 7 | a https://doi.org/10.3109/0284186X.2015.10492902 DOI |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2680872 URI |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1328841472 URI |
| 040 | a (SwePub)umud (SwePub)uud (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Ekman, Simonu Karolinska Institutet,Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)simoekma |
| 245 | 1 0 | a A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma :b A phase I clinical trial |
| 264 | 1 | c 2016 |
| 338 | a print2 rdacarrier | |
| 520 | a BACKGROUND: A phase Ia/b dose-escalation study was performed to characterize the safety, efficacy and pharmacokinetic properties of the oral small molecule insulin-like growth factor-1-receptor pathway modulator AXL1717 in patients with advanced solid tumors.MATERIAL AND METHODS: This was a prospective, single-armed, open label, dose-finding phase Ia/b study with the aim of single day dosing (phase Ia) to define the starting dose for multi-day dosing (phase Ib), and phase Ib to define and confirm recommended phase II dose (RP2D) and if possible maximum tolerated dose (MTD) for repeated dosing.RESULTS AND CONCLUSION: Phase Ia enrolled 16 patients and dose escalations up to 2900 mg BID were successfully performed without any dose limiting toxicity (DLT). A total of 39 patients were treated in phase Ib. AXL1717 was well tolerated with neutropenia as the only dose-related, reversible, DLT. RP2D dose was found to be 390 mg BID for four weeks. Some patients, mainly with NSCLC, demonstrated signs of clinical benefit, including four partial tumor responses (one according to RECIST and three according to PET). The 15 patients with NSCLC with treatment duration longer than two weeks with single agent AXL1717 in third or fourth line of therapy showed a median progression-free survival of 31 weeks and overall survival of 60 weeks. Down-regulation of IGF-1R on granulocytes and increases of free serum levels of IGF-1 were seen in patients treated with AXL1717. AXL1717 had an acceptable safety profile and demonstrated promising efficacy in this heavily pretreated patient cohort, especially in patients with NSCLC. RP2D was concluded to be 390 mg BID for four weeks. Trial number is NCT01062620. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
| 653 | a onkologi | |
| 653 | a Oncology | |
| 700 | 1 | a Harmenberg, Johan4 aut |
| 700 | 1 | a Frödin, Jan-Eriku Karolinska Institutet4 aut |
| 700 | 1 | a Bergström, Stefan4 aut |
| 700 | 1 | a Wassberg, Ceciliau Uppsala universitet,Radiologi4 aut0 (Swepub:uu)ceciwass |
| 700 | 1 | a Eksborg, Staffanu Karolinska Institutet4 aut |
| 700 | 1 | a Larsson, Olleu Karolinska Institutet4 aut |
| 700 | 1 | a Axelson, Magnusu Karolinska Institutet4 aut |
| 700 | 1 | a Jerling, Markus4 aut |
| 700 | 1 | a Abrahmsen, Lars4 aut |
| 700 | 1 | a Hedlund, Åsa4 aut |
| 700 | 1 | a Alvfors, Carinau Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)carialvf |
| 700 | 1 | a Ståhl, Birgitta4 aut |
| 700 | 1 | a Bergqvist, Michaelu Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden4 aut0 (Swepub:umu)mibe0079 |
| 710 | 2 | a Uppsala universitetb Experimentell och klinisk onkologi4 org |
| 773 | 0 | t Acta Oncologicag 55:2, s. 140-148q 55:2<140-148x 0284-186Xx 1651-226X |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-120005 |
| 856 | 4 8 | u https://doi.org/10.3109/0284186X.2015.1049290 |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-268087 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:132884147 |
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Ekman, Simon
- Harmenberg, Joha ...
- Frödin, Jan-Erik
- Bergström, Stefa ...
- Wassberg, Cecili ...
- Eksborg, Staffan
- visa fler...
- Larsson, Olle
- Axelson, Magnus
- Jerling, Markus
- Abrahmsen, Lars
- Hedlund, Åsa
- Alvfors, Carina
- Ståhl, Birgitta
- Bergqvist, Micha ...
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
- Artiklar i publikationen
- Acta Oncologica
- Av lärosätet
- Umeå universitet
- Uppsala universitet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
